Rx Label "Highlights" Under FDA Rule Could Yield Inconsistencies - Merck

Information included in the "Highlights" summary section of drug labeling under FDA's proposed rule would likely be inconsistent from product to product, Merck said in comments on FDA's proposed labeling rule.

More from Archive

More from Pink Sheet